دورية أكاديمية

Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results.

التفاصيل البيبلوغرافية
العنوان: Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results.
المؤلفون: Hong, Jin-Bon, Wu, Po-Yuan, Qin, Albert, Huang, Yi-Wen, Tseng, Kuan-Chiao, Lai, Ching-Yu, Chan, Wing-Kai, Fang, Jane, Cutler, David L., Tsai, Tsen-Fang
المصدر: Pharmaceutics; Oct2022, Vol. 14 Issue 10, pN.PAG-N.PAG, 12p
مصطلحات موضوعية: FOUR day week, PSORIASIS, TUBULINS, ACTINIC keratosis, DISEASE relapse, POLYMERIZATION
مصطلحات جغرافية: TAIWAN
مستخلص: Plaque-type psoriasis is a common skin disorder. Tirbanibulin (KX01) is a new Src kinase inhibitor with potent antiproliferative activity against keratinocytes and has been approved for treatment of actinic keratosis. This Phase I study investigates the safety and activity of KX01 ointment in patients with plaque-type psoriasis. We recruited 28 patients from two medical centers in Taiwan. This study was performed in four stages. Double-blind treatments were randomized in stages I (KX01 0.01% + placebo, two rounds of two-week treatment) and II (KX01 0.1% + placebo, four weeks) and open-labelled in stages III (KX01 1%, five days) and IV (KX01 1%, five days weekly for four weeks). The safety, tolerability, KX01 concentration, target area score, physician global assessment, and disease relapse were determined. Most treatment-emergent adverse events were mild-to-moderate application site reactions. Three (50.0%) subjects from the stage IV group showed ≥50% reduction in the target area score (TAS50), while two subjects (33.3%) showed a clinically meaningful improvement in the physician global assessment score. KX01 0.01%, 0.1%, and 1% were safe and well-tolerated. KX01 1% at four weeks showed a promising activity for the treatment of plaque-type psoriasis. [ABSTRACT FROM AUTHOR]
Copyright of Pharmaceutics is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:19994923
DOI:10.3390/pharmaceutics14102159